FINWIRES · TerminalLIVE
FINWIRES

摩根士丹利稱,泰瑞達業績反映出預期問題,人工智慧網路前景趨於平穩。

By

-- 摩根士丹利週四在一份報告中指出,泰瑞達(TER)的業績反映的是“預期問題”,而非業績不如預期。儘管矽光子學/共封裝光學元件的中期市場規模預計將成長至3億至7億美元,但投資人對人工智慧網路及相關測試機會的樂觀情緒仍需謹慎對待。 然而,該券商表示,市場對網路技術的預期需要降低,並補充說,泰瑞達聲稱其市場份額與競爭對手愛德萬測試(Advantest)持平的說法“令人沮喪”,尤其考慮到網絡技術歷來是該公司的優勢領域。 摩根士丹利也對英偉達(NVDA)GPU的機會持謹慎態度。報告指出,儘管泰瑞達已獲得初步的生產測試訂單,但長期規模和市場份額的成長仍存在不確定性,且尚未完全反映在投資者的預期中。 泰瑞達(Teradyne)調整了其2026年營收預期,將全年營收預期下半年佔比略微提高,預計全年營收為41.4億美元至45.1億美元。下限反映了人工智慧資料中心建置可能出現的波動,而上限則假設運算、網路和記憶體需求將持續強勁成長。 摩根士丹利將泰瑞達2026年的營收和每股盈餘預期分別從47.3億美元和7.25美元上調至47.5億美元和8.03美元。同時,摩根士丹利也將泰瑞達2027年的營收和每股盈餘預期分別從63億美元和11.05美元上調至63億美元和11.37美元。 摩根士丹利將泰瑞達的目標股價從376美元上調至387美元,並維持「中性」評級。 週四,泰瑞達股價上漲超過14%。

Price: $350.14, Change: $+43.81, Percent Change: +14.30%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM